Andrew Kenneth William Powell

Insider Reports History

Identity
Location
Newtown, PA
SEC record
Reporting signature
/s/ Matthew Rothman, Attorney-in-Fact
SEC evidence
Transaction evidence
Report rows are grouped by the transaction date disclosed in the original SEC filing. Open the aggregated insider activity page to review issuer-level activity across dates.

Holdings reported by Andrew Kenneth William Powell:

Form 4 holding Director

LANDEC CORP \CA\

Security class
Common Stock
Shares / value
27,477
Estimated value
$286,310
Report date
04 Jun 2022
Price
$10.42
Ownership
Direct
Form 4 holding Director

Aclaris Therapeutics, Inc.

Security class
Restricted Stock Units
Shares / value
0
Estimated value
$0
Report date
01 Jun 2024
Price
$1.26
Ownership
Direct
Underlying class
Common Stock
Underlying amount
Form 4 holding Director

Silverback Therapeutics, Inc.

Security class
Stock Option (right to buy)
Shares / value
18,000
Estimated value
Report date
10 Jun 2022
Price
Ownership
Direct
Underlying class
Common Stock
Underlying amount
Form 4 holding Director

Aclaris Therapeutics, Inc.

Security class
Stock Option (Right to Buy)
Shares / value
15,750
Estimated value
Report date
01 Jun 2023
Price
Ownership
Direct
Underlying class
Common Stock
Underlying amount
Form 4 holding Director

LANDEC CORP \CA\

Security class
Restricted Stock Unit
Shares / value
0
Estimated value
Report date
04 Jun 2022
Price
$7.00
Ownership
Direct
Underlying class
Common Stock
Underlying amount

Insider Reports Filed by Andrew Kenneth William Powell

We use cookies and similar technologies to provide certain features, enhance the user experience and, if you allow them, measure engagement and deliver advertising. Analytics and marketing storage stay off until you grant consent. By clicking on "Agree and continue", you declare your consent to the use of the selected optional cookies. Manage preferences to update or revoke optional consent for future visits. For more information, see our Privacy Policy .